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Case report
Falsely elevated serum tobraycin levels in a patient receiving nebulised
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Abstract
It is common when treating patients with respiratory exacerbations of cystic fibrosis to use both nebulised and intravenous
antibiotics. Aminoglycoside drug levels are often measured from finger-prick blood samples. We describe a case of a 14-year-old
girl treated simultaneously with IV and nebulised tobramycin in whom drug levels, measured from finger prick blood samples,
were erroneously high due to finger contamination by the nebulised drug. Special precautions or direct venepuncture is essential
when assessing antibiotic levels in such patients.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Intravenous (IV) aminoglycosides are well-estab-
lished antibiotics for the treatment of pulmonary sepsis
in conditions such as cystic fibrosis. Careful monitoring
of drug levels is mandatory to ensure that sufficient
peak concentrations are achieved for concentration
dependent killing but also to ensure adequate clearance
to safe trough levels thus minimising the risks of side
effects such as nephrotoxicity and ototoxicity. In recent
years nebulised aminoglycoside antibiotics have also
been used in the management of chronic Pseudomonas
aeruginosa infection w1x. Their efficacy in respiratory
conditions such as chronic bronchitis is currently being
assessed in clinical trials. The aims of this strategy are
to reduce the bacterial load of infecting pathogens,
improve lung function and reduce the number of acute
exacerbations. However, when respiratory exacerbations
occur it is common practice to give a course of two or
more intravenous antibiotics including an aminoglyco-
side in addition to the nebulised antibiotic. Such patients
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might simultaneously receive the same aminoglycoside
by nebuliser and IV injection. In this report we describe
a case where simultaneous treatment with nebulised and
IV tobramycin led to contamination of the fingers and
resulted in falsely high estimates of serum tobramycin
levels.
2. Case
A 14-year-old female with cystic fibrosis was receiv-
ing regular medication with nebulised tobramycin
(TOBI) 300 mg twice daily according to its licensed
indication for 28 day on and 28 day off cycles. She was
admitted for a course of additional IV antibiotics to treat
increased sputum production, reduced exercise tolerance
and a greater than 10% deterioration in lung function.
Renal indices were normal at the start of treatment. Her
initial antibiotic regime was intravenous ceftazidime 2 g,
three times daily plus tobramycin 10 mgykgyday given
in three divided doses. In keeping with current recom-
mendations we did not interrupt her nebulised tobra-
mycin. Tobramycin levels taken from finger prick
specimens around her fourth dose were elevated with
trough levels of 2.5 mgyl (our target range -1 mgyl)
and a peak of 12.5 mgyl (target range 7–10 mgyl). As
a result the tobramycin dosage was reduced and the
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dosage interval increased. To assess subsequent renal
clearance a further tobramycin level was measured
before the next dose of intravenous antibiotic. The level
was 27.6 mgyl despite no parenteral tobramycin having
been given in the preceding 18 h. Sample contamination
was suspected. To confirm this a series of tobramycin
levels following the next nebulised tobramycin dose
(but no further IV dose) were collected. A venous blood
level from the right antecubital fossa was -1 mgyl. A
blood level from a right index finger prick was 18.5
mgyl. Saline washings (1 ml) from the end of the right
middle finger gave a level of 77 mgyl. After handwash-
ing with antiseptic soap and water, a repeat right index
finger prick blood level remained falsely high at 6.8
mgyl. Resumption of our standard IV tobramycin regime
resulted in optimal serum levels according to assays
from further venous samples.
3. Discussion
This case highlights the care needed when monitoring
drug levels in patients receiving concurrent nebulised
and IV aminoglycosides. Erroneously high toxic drug
levels were obtained from finger prick blood samples
taken from the hand used to hold the nebuliser for
administering tobramycin. This occurred despite our
routine measures to minimise the escape of nebulised
antibiotic into the atmosphere. We use a Pari-LC Plus
nebuliser system and attach elephant tubing via a Y
connector fitted with a non-return valve between the
mouthpiece and nebuliser. Exhaled drug is thus con-
ducted through the tubing and out through an open
window to the open air. This practice was insufficient
to prevent significant drug deposition on the patient’s
fingers.
The use of finger prick samples for aminoglycoside
assays is accepted practice in most CF centres. The ease
with which such samples can be collected has made
them a favoured option, particularly for patients receiv-
ing intravenous antibiotics at home. The alternative of
repeated venepuncture is unpopular with many patients
and especially those in the paediatric population. One
previous study has highlighted the problem of falsely
elevated serum aminoglycoside levels after nebuliser
inhalations w2x. The authors suggested either wearing
gloves or thorough hand washing between nebuliser
dosages and the taking of finger prick samples. We have
shown that handwashing might not be sufficient to rid
the fingers of aminoglycoside contamination. Thus far
wearing gloves has not validated as a method of elimi-
nating contamination. We conclude that venupuncture is
the preferred option for taking drug levels when the
same aminoglycoside is being administered both intra-
venously and nebulised.
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